ARCTArcturus Therapeutics Holdings Inc
$7.16
$0.04
(0.56%)
Closed $7.16
$0.00
(0.00%)
After Hours
EarningsAug 10
Mkt Cap$202.37M
Vol242,351.00
Fundamentals
Mkt Cap
$202.37M
Volume
-
52W High
$24.17
52W Low
$5.85
PE Ratio
-2.54
Avg. Volume
461,268.70
EPS (Annual)
-$2.40
Rev/Employee
$605,594.60
Earnings
Aug 10
26
Bearish Sentiment
How do you feel about ARCT?
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in New York: 2026 Jefferies...
Business Wire
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +16.91% and -73.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today...
Business Wire
Arcturus Therapeutics (ARCT) Projected to Post Earnings on Thursday
Arcturus Therapeutics (NASDAQ:ARCT) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...
MarketBeat
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates
Illumina (ILMN) delivered earnings and revenue surprises of +9.70% and +1.15%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Arcturus Therapeutics (NASDAQ:ARCT) Shares Cross Below 200 Day Moving Average - Time to Sell?
Arcturus Therapeutics (NASDAQ:ARCT) Stock Passes Below 200-Day Moving Average - What's Next...
MarketBeat
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today...
Business Wire
Diversify Advisory Services LLC Sells 115,500 Shares of Arcturus Therapeutics Holdings Inc. $ARCT
Diversify Advisory Services LLC reduced its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 88.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,00...
MarketBeat
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of "Moderate Buy" from Brokerages
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the thirteen brokerages that are currently covering the firm...
MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below Two Hundred Day Moving Average - What's Next?
Arcturus Therapeutics (NASDAQ:ARCT) Stock Passes Below Two Hundred Day Moving Average - What's Next...
MarketBeat
<
1
2
...
>